Moxidectin is under clinical development by Medicines Development for Global Health and currently in Phase I for Elephantiasis (Lymphatic Filariasis). According to GlobalData, Phase I drugs for Elephantiasis (Lymphatic Filariasis) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Moxidectin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Moxidectin is a semisynthetic derivative of nemadectin and acts as an anthelmintic agent. It is formulated as tablets for oral route of administration. Moxidectin is indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older. Moxidectin is under investigation for the treatment of scabies, onchocerciasis in children, soil-transmitted helminths, strongyloides, lymphatic filariasis and head lice.
Medicines Development for Global Health overview
Medicines Development for Global Health (MDGHL) is an independent biopharmaceutical company that strives to develop and commercialize medicines and vaccines for unmet medical needs. The company’s pipeline clinical programs include Moxidectin, which is being developed for the treatment of river blindness and scabies; and RV-3-BB rotavirus vaccine, for prevention of rotavirus gastroenteritis in infants and neonates. It is also developing products which are in Phase I and II clinical development, for soil-transmitted helminthes, strongyloides and lymphatic filariasis. MDGHL is headquartered in Melbourne, Victoria, Australia.
For a complete picture of Moxidectin’s drug-specific PTSR and LoA scores, buy the report here.